Laron syndrome

Last updated

Laron syndrome
Other namesgenetic pituitary dwarfism (1966), Laron dwarfism (1973), Laron-type dwarfism (1984), growth hormone insensitivity (1994), hereditary somatomedin deficiency, growth hormone receptor deficiency (GHRD)(1999) [1]
Somatotropine.GIF
Growth hormone
Specialty Endocrinology, Medical Genetics, Pediatrics
Symptoms Short stature, truncal obesity, facial dysmorphism [2]
Usual onsetPresent at birth
DurationLifelong
Causes Autosomal recessive growth hormone receptor gene mutation (chromosome 5) [2]
Risk factors Hypoglycemia, seizures, reduced intellectual capacity, osteopenia [2]
Differential diagnosis STAT5b, IGF1 gene mutation, ALS deficiency, IGF-1 receptor mutation, familial short stature, malnutrition, hepatic disease, congenital growth delay, hypopituitarism [1]
Treatment IGF-1, Mecasermin [3]
Frequency1–9 / 1,000,000 (approximately 250 known cases worldwide) [4] [5]

Laron syndrome (LS), also known as growth hormone insensitivity or growth hormone receptor deficiency (GHRD), is an autosomal recessive disorder characterized by a lack of insulin-like growth factor 1 (IGF-1; somatomedin-C) production in response to growth hormone (GH; hGH; somatotropin). [6] It is usually caused by inherited growth hormone receptor (GHR) mutations. [2] [6]

Contents

Affected individuals classically present with short stature between −4 and −10 standard deviations below median height, obesity, craniofacial abnormalities, micropenis, low blood sugar, and low serum IGF-1 despite elevated basal serum GH. [7] [5] [8]

LS is a very rare condition with a total of 250 known individuals worldwide. [4] [5] The genetic origins of these individuals have been traced back to Mediterranean, South Asian, and Semitic ancestors, with the latter group comprising the majority of cases. [5] Molecular genetic testing for growth hormone receptor gene mutations confirms the diagnosis of LS, but clinical evaluation may include laboratory analysis of basal GH, IGF-1 and IGFBP levels, GH stimulation testing, and/or GH trial therapy.

People with LS are unresponsive to growth hormone therapy; the disease is instead treated mainly with recombinant IGF-1, Mecasermin. [3]

Evidence has suggested that people with Laron syndrome have a reduced risk of developing cancer and diabetes mellitus type II, with a significantly reduced incidence and delayed age of onset of these diseases compared to their unaffected relatives. [9] [10] The molecular mechanisms of increased longevity and protection from age-related disease among people with LS is an area of active investigation. [11]

Presentation

Physical features

LS is recognized as being part of a spectrum of conditions that affect the Hypothalamic–pituitary–somatotropic axis and cause significant derangements in human growth, development, and metabolism. [1] [6] Along this spectrum of conditions, individuals with LS and growth hormone deficiency display short stature, while individuals with acromegaly and gigantism result in the opposite phenotype of tall stature. [1] [12]

In addition to short stature, other characteristic physical symptoms of LS include: prominent forehead, depressed nasal bridge, underdevelopment of mandible, truncal obesity, [7] and micropenis in males. Left untreated, the average height attained by individuals with LS are approximately 4–4.5 feet (1.2–1.4 m) in women/men respectively. [13] Additional physical features include delayed bone age, hypogonadism, blue sclera, high-pitched voice, acrohypoplasia, sparse hair growth, and crowded teeth. [14] The breasts of females reach normal size, and in some are large in relation to body size. [6] It has been suggested that hyperprolactinemia may contribute to the enlarged breast size. [9] Seizures are frequently seen secondary to hypoglycemia. Some genetic variations decrease intellectual capacity. [15] Laron syndrome patients also do not develop acne, except temporarily during treatment with IGF-1 (if performed). [9]

Pathophysiology

Laron syndrome has an autosomal recessive pattern of inheritance. Autorecessive.svg
Laron syndrome has an autosomal recessive pattern of inheritance.
Figure 37 03 07.png
Impact of insulin/IGF-1 signaling in Laron syndrome (A) and Western diet (B) on FoxO-mediated gene regulation and associated pathologies. GHR*, growth hormone receptor loss of function mutation in Laron syndrome; GIP, glucose-dependent insulinotropic polypeptide, a whey protein-induced incretin, which stimulates b-cell proliferation and insulin secretion; PRL, prolactin; PRL secretion is induced by serotoninergic hypothalamic signaling; Trp, tryptophan, and Leu, leucine, essential amino acids enriched in the whey protein a-lactalbumin; Trp via serotonin synthesis stimulates pituitary GH and PRL secretion and Leu stimulates b-cell proliferation and insulin secretion. Laron syndrome 01.jpg
Impact of insulin/IGF-1 signaling in Laron syndrome (A) and Western diet (B) on FoxO-mediated gene regulation and associated pathologies. GHR*, growth hormone receptor loss of function mutation in Laron syndrome; GIP, glucose-dependent insulinotropic polypeptide, a whey protein-induced incretin, which stimulates β-cell proliferation and insulin secretion; PRL, prolactin; PRL secretion is induced by serotoninergic hypothalamic signaling; Trp, tryptophan, and Leu, leucine, essential amino acids enriched in the whey protein α-lactalbumin; Trp via serotonin synthesis stimulates pituitary GH and PRL secretion and Leu stimulates β-cell proliferation and insulin secretion.

Under normal circumstances in humans, growth hormone (GH) is released in a pulsatile fashion from cells known as somatotrophs in the anterior pituitary gland. [16] These pulses of GH are regulated by cells in the hypothalamus, via the release of growth hormone-releasing hormone (GHRH) into the hypothalamohypophysial system when stimulated by insulin, ghrelin, glucagon, arginine, deep sleep, exercise, fasting, sex hormone release during puberty, and a host of other factors. [16] GH release is inhibited by somatostatin (GHIH), IGF-1, hyperglycemia, and glucocorticoids. [16] Once released, the GH molecules travel through the bloodstream and eventually bind to GH receptors on the surface of cells composing bodily organs and tissues. [16] One major site of action for GH is in the liver, where it stimulates gluconeogenesis and the release of IGF-1 through the JAK-STAT signaling pathway. [16] IGF-1 promotes growth in a variety of tissues throughout the body, especially bone mineralization, and provides negative feedback on GH release. [16] GH results in increased muscle mass, lipolysis, and protein synthesis. [16] Obesity and increased adipose tissue, especially visceral fat, results in reduced GH secretion. [16] There is a natural age-related decline in the GHRH-stimulated release of GH. [16]

Growth hormone receptor mutations

Molecular genetic investigations have shown that LS is mainly associated with autosomal recessive mutations in the gene for the growth hormone receptor (GHR). [6] [17] These can result in defective hormone binding to the ectodomain or reduced efficiency of dimerization of the receptor after hormone occupancy. [18]

LS is generally classified as "primary" GH insensitivity, which is distinguished from "secondary" GH insensitivity. [1] Primary (congenital/hereditary) GH insensitivity may result from growth hormone receptor defects, as in the case of Laron syndrome, but can also be caused by defective post-receptor signal transduction (STAT5B), abnormalities of the IGF-1 gene or IGF-1 receptor. [2] [1] Secondary (acquired) GH insensitivity results from antibodies to growth hormone or the growth hormone receptor, as well as poor nutritional status, liver disease or diabetes mellitus. [5] [6] A GHR mutation that results in only partial insensitivity to GH can manifest as a form of idiopathic short stature. [2] [8]

STAT5B

A related condition involving postreceptor insensitivity to growth hormone has been associated with STAT5B. [19]

Diagnosis

LS should be suspected in children or adults with distinctive physical features listed above, extremely elevated serum hGH concentrations despite low serum IGF-1 levels. [14] A failure of IGF-1 to increase in response to exogenous hGH (IGF-1 stimulation test) is diagnostic for LS. [14] The gold standard for confirming a diagnosis of LS is to perform a genetic analysis with PCR to identify the precise molecular defect in the GH receptor gene. [14] Other laboratory abnormalities include GHBP (growth hormone binding protein) levels being low in cases with mutations in the extracellular domain of the GH receptor and normal in cases with mutations in the intracellular domain. Low serum levels of IGFBP are non-diagnostic for LS. [14]

Treatment

Administration of recombinant GH has no effect on IGF-1 production, therefore it is ineffective for the treatment of Laron syndrome. [20] Instead, it is treated mainly by recombinant IGF-1. [21] IGF-1 must be taken before puberty to be effective. [22] [ medical citation needed ]

The drug product Increlex (mecasermin), developed by the company Tercica, purchased by Ipsen, was approved by the US Food and Drug Administration in August 2005 for replacing IGF-1 in patients who are deficient. [23]

IPLEX (Mecasermin rinfabate) is composed of recombinant human IGF-1 (rhIGF-1) and its binding protein IGFBP-3. It was approved by the U.S. Food and Drug Administration (FDA) in 2005 for treatment of primary IGF-1 deficiency or GH gene deletion. [24] [25] Side effects from IPLEX are hypoglycemia. IPLEX's manufacturing company, Insmed, after selling its protein production facility, can no longer develop proteins, thus can no longer manufacture IPLEX as of a statement released in July 2009. [26]

In Ecuador, despite having the highest number of Laron syndrome cases in the world, affected children lacked proper treatment. In 2010 and 2014, a group of parents, led by Santiago Vasco Morales, filed lawsuits requesting the Ecuadorian government to provide the necessary comprehensive treatment. However, due to the lack of response and non-compliance with court rulings, the parents sought assistance from the Inter-American Commission on Human Rights (IACHR). Only after an admissibility report was issued by the IACHR on April 24, 2020 [27] did the Ecuadorian state begin administering the treatment. Unfortunately, many patients who needed IGF-1 treatment were unable to benefit from it, as they reached adulthood without receiving this essential medication. This was due to the unjustified refusal of the Ecuadorian state to provide such treatment for more than a decade. [28]

Prognosis

Cancer and diabetes

It has been reported that people with LS in Ecuador are resistant to cancer and diabetes and are somewhat protected against aging. [29] [30] [31] This is consistent with findings in mice with a defective growth hormone receptor gene. [22] Among the approximately 100 individuals in this population, there were no reported cases of diabetes and one case of cancer. [32]

A 2019 study of individuals with isolated growth hormone deficiency (IGHD type 1B) in Itabaianinha County, Brazil, demonstrated a phenotype consistent with Laron syndrome. [33] Researchers found that these humans had similarly extended healthspan, with resistance to cancer and attenuated effects of aging, but neither patients with LS nor IGHD experienced an increase in their overall lifespan. [33]

Incidence

Numerous Laron syndrome patients are found in Israel among the country's diverse Jewish population composed of Jews from around the world, as well as patients outside Israel originally from communities of the Jewish diaspora, such as Egypt and Iraq. The original "Israeli cohort" of patients referred to Zvi Laron and colleagues beginning in 1958 consisted of 64 patients as of 2009, including 4 deceased patients. [1] The countries of origin of these patients include Israel, Palestine, Jordan, Lebanon, Iran, Malta, Italy, Argentina, Ecuador, and Peru. [1]

A disproportionate number of people with the condition are found in remote villages in the Loja province of Ecuador. These individuals are descended from colonial-era Jewish-origin New Christian conversos (Sephardi Jews who themselves, or whose forebears, had been compelled to convert to Catholicism back in Spain) who had covertly migrated to Ecuador during the Spanish Conquest despite the Spanish Crown's prohibition of their emigration to its colonies and territories as a result of the Inquisition. [29] [22] [5] [2] [34]

Other patients include people of other Semitic non-Jewish origins, including from Saudi Arabia, Japan, and China. [1]

Homo floresiensis

Recent publications have proposed that Homo floresiensis represented a population with widespread Laron syndrome, based upon the many similarities of skeletal remains found in Indonesia with LS. [35] [36] This is only one of several competing hypotheses, and has received criticism as insufficient to explain the "range features observed in H. floresiensis". [37] Similar postulates have been proposed regarding the Pygmies of Central Africa. [38]

History

Israeli pediatric endocrinologist Zvi Laron, along with Athalia Pertzelan, Avinoam Galatzer, Liora Kornreich, Dalia Peled, Rivka Kauli, and Beatrice Klinger published the earliest clinical studies of individuals with LS beginning in 1966. [39] [40] [1] Among their first 22 patients, Laron and colleagues noted consanguineous genealogy of Israeli and Palestinian ancestry with distinct physical characteristics resembling hypopituitarism. [1] [6] However, researchers noticed that these people had high serum GH levels, which are expected to be low in patients with hypopituitarism. [1] Successive studies carried out over the subsequent 20 years by Laron and colleagues revealed an absence of IGF-1 release in response to exogenous hGH and an absence of GH binding to liver cell membranes in this group of patients. [1] The results of these studies provided clear evidence that the pathogenicity of the disease was the result of GH receptor failure in the liver. [1]

See also

Related Research Articles

<span class="mw-page-title-main">Growth hormone</span> Peptide hormone, that stimulates growth

Growth hormone (GH) or somatotropin, also known as human growth hormone in its human form, is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration in humans and other animals. It is thus important in human development. GH also stimulates production of Insulin-like growth factor 1 (IGF-1) and increases the concentration of glucose and free fatty acids. It is a type of mitogen which is specific only to the receptors on certain types of cells. GH is a 191-amino acid, single-chain polypeptide that is synthesized, stored and secreted by somatotropic cells within the lateral wings of the anterior pituitary gland.

<span class="mw-page-title-main">Gigantism</span> Human growth disorder

Gigantism, also known as giantism, is a condition characterized by excessive growth and height significantly above average. In humans, this condition is caused by over-production of growth hormone in childhood.

<span class="mw-page-title-main">Growth hormone deficiency</span> Medical condition

Growth hormone deficiency (GHD), or human growth hormone deficiency, is a medical condition resulting from not enough growth hormone (GH). Generally the most noticeable symptom is that an individual attains a short height. Newborns may also present low blood sugar or a small penis size. In adults there may be decreased muscle mass, high cholesterol levels, or poor bone density.

<span class="mw-page-title-main">Insulin-like growth factor 1</span> Protein found in humans

Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a hormone similar in molecular structure to insulin which plays an important role in childhood growth, and has anabolic effects in adults. In the 1950s IGF-1 was called "sulfation factor" because it stimulated sulfation of cartilage in vitro, and in the 1970s due to its effects it was termed "nonsuppressible insulin-like activity" (NSILA).

Idiopathic short stature (ISS) refers to extreme short stature that does not have a diagnostic explanation after an ordinary growth evaluation. The term has been in use since at least 1975 without a precise percentile or statistical definition of "extreme".

<span class="mw-page-title-main">Pituitary adenoma</span> Human disease

Pituitary adenomas are tumors that occur in the pituitary gland. Most pituitary tumors are benign, approximately 35% are invasive and just 0.1% to 0.2% are carcinomas. Pituitary adenomas represent from 10% to 25% of all intracranial neoplasms and the estimated prevalence rate in the general population is approximately 17%.

<span class="mw-page-title-main">Zvi Laron</span> Israeli pediatric endocrinologist

Zvi Laron is an Israeli paediatric endocrinologist. Born in Cernăuţi, Romania, Laron is a professor emeritus at Tel Aviv University. In 1966, he described the type of dwarfism later called Laron syndrome. His research opened the way to the treatment of many cases of growth hormone disorders. He was the first to introduce the multidisciplinary treatment for juvenile diabetes.

<span class="mw-page-title-main">Growth hormone receptor</span> A protein involved in the binding of the growth hormone

Growth hormone receptor is a protein that in humans is encoded by the GHR gene. GHR orthologs have been identified in most mammals.

Growth hormone-binding protein (GHBP) is a soluble carrier protein for growth hormone (GH). The full range of functions of GHBP remains to be determined however, current research suggests that the protein is associated with regulation of the GH availability and half-life in the circulatory system, as well as modulating GH receptor function.

<span class="mw-page-title-main">Growth-hormone-releasing hormone receptor</span> Receptor protein that binds with somatcrinin

The growth-hormone-releasing hormone receptor (GHRHR) is a G-protein-coupled receptor that binds growth hormone-releasing hormone. The GHRHR activates a Gs protein that causes a cascade of cAMP via adenylate cyclase. GHRHR is distinct from the growth hormone secretagogue receptor, where growth hormone releasing peptides act to release growth hormone.

Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. It is delivered as a powder that is mixed with water and injected under the skin.

Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome.

<span class="mw-page-title-main">Aromatase deficiency</span> Medical condition

Aromatase deficiency is a rare condition characterized by extremely low levels or complete absence of the enzyme aromatase activity in the body. It is an autosomal recessive disease resulting from various mutations of gene CYP19 (P450arom) which can lead to ambiguous genitalia and delayed puberty in females, continued linear growth into adulthood and osteoporosis in males and virilization in pregnant mothers. As of 2020, fewer than 15 cases have been identified in genetically male individuals and at least 30 cases in genetically female individuals.

Breast development, also known as mammogenesis, is a complex biological process in primates that takes place throughout a female's life.

<span class="mw-page-title-main">John Kopchick</span> American biologist

John Kopchick is a molecular biologist and co-inventor of the drug Somavert (Pegvisomant), which has improved the lives of acromegalic individuals around the world. He is currently the Goll-Ohio Eminent Scholar and Professor of Molecular Biology in the Department of Biomedical Sciences at the Ohio University Heritage College of Osteopathic Medicine. Dr. Kopchick's groundbreaking work in the field of growth hormone has helped shape the study of endocrinology.

<span class="mw-page-title-main">Floating–Harbor syndrome</span> Medical condition

Floating–Harbor syndrome, also known as Pelletier–Leisti syndrome, is a rare disease with fewer than 50 cases described in the literature. It is usually diagnosed in early childhood and is characterized by the triad of proportionate short stature with delayed bone age, characteristic facial appearance, and delayed speech development. Although its cause is unknown, it is thought to result from genetic mutation, and diagnosis is established by the presence of a heterozygous SRCAP mutation in those with clinical findings of FHS.

Gonadotropin-releasing hormone (GnRH) insensitivity also known as Isolated gonadotropin-releasing hormone (GnRH)deficiency (IGD) is a rare autosomal recessive genetic and endocrine syndrome which is characterized by inactivating mutations of the gonadotropin-releasing hormone receptor (GnRHR) and thus an insensitivity of the receptor to gonadotropin-releasing hormone (GnRH), resulting in a partial or complete loss of the ability of the gonads to synthesize the sex hormones. The condition manifests itself as isolated hypogonadotropic hypogonadism (IHH), presenting with symptoms such as delayed, reduced, or absent puberty, low or complete lack of libido, and infertility, and is the predominant cause of IHH when it does not present alongside anosmia.

<span class="mw-page-title-main">Kowarski syndrome</span> Medical condition

Kowarski syndrome describes cases of growth failure, despite the presence of normal or slightly high blood growth hormone by radioimmunoassay (RIA-GH) and low serum IGF1, and who exhibit a significant increase in growth rate following recombinant GH therapy.

Acromesomelic dysplasia is a rare skeletal disorder that causes abnormal bone and cartilage development, leading to shortening of the forearms, lower legs, hands, feet, fingers, and toes. Five different genetic mutations have been implicated in the disorder. Treatment is individualized but is generally aimed at palliating symptoms, for example, treatment of kyphosis and lumbar hyperlordosis.

<span class="mw-page-title-main">Hypothalamic–pituitary–somatotropic axis</span>

The hypothalamic–pituitary–somatotropic axis, or hypothalamic–pituitary–somatic axis, also known as the hypothalamic–pituitary–growth axis, is a hypothalamic–pituitary axis which includes the secretion of growth hormone from the somatotropes of the pituitary gland into the circulation and the subsequent stimulation of insulin-like growth factor 1 production by GH in tissues such as, namely, the liver. Other hypothalamic–pituitary hormones such as growth hormone-releasing hormone, growth hormone-inhibiting hormone, and ghrelin (GHS) are involved in the control of GH secretion from the pituitary gland. The HPS axis is involved in postnatal human growth. Individuals with growth hormone deficiency or Laron syndrome show symptoms like short stature, dwarfism and obesity, but are also protected from some forms of cancer. Conversely, acromegaly and gigantism are conditions of GH and IGF-1 excess usually due to a pituitary tumor, and are characterized by overgrowth and tall stature.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Laron Z, Kopchick J (25 November 2010). Laron Syndrome - From Man to Mouse: Lessons from Clinical and Experimental Experience. Springer Science & Business Media. pp. 3–6. ISBN   978-3-642-11183-9 . Retrieved 10 November 2020.
  2. 1 2 3 4 5 6 7 Hamosh A, O'Neill M, Phillips J, McKusick V. "# 262500 LARON SYNDROME". omim.org. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine. Retrieved 10 November 2020.
  3. 1 2 Grimberg A, DiVall SA, Polychronakos C (2016). "Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency". Hormone Research in Paediatrics. 86 (6): 361–397. doi: 10.1159/000452150 . PMID   27884013. S2CID   5798925.
  4. 1 2 Leger J. "ORPHA:633". orpha.net. Retrieved 30 October 2020.
  5. 1 2 3 4 5 6 Rosenbloom AL (13 November 2019). "Growth Hormone Resistance". Medscape Reference. Retrieved 3 November 2020.
  6. 1 2 3 4 5 6 7 Laron Z (2004). "Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity): The Personal Experience 1958–2003". The Journal of Clinical Endocrinology & Metabolism. 89 (3): 1031–1044. doi: 10.1210/jc.2003-031033 . ISSN   0021-972X. PMID   15001582.
  7. 1 2 Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N (2006). "Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity)". Clin. Endocrinol. 65 (1): 114–7. doi:10.1111/j.1365-2265.2006.02558.x. PMID   16817829. S2CID   11524548.
  8. 1 2 Murray PG, Clayton PE (16 November 2016). Disorders of Growth Hormone in Childhood. MDText.com, Inc. PMID   25905205 . Retrieved 3 November 2020.
  9. 1 2 3 Laron Z, Kopchick J (25 November 2010). Laron Syndrome - From Man to Mouse: Lessons from Clinical and Experimental Experience. Springer Science & Business Media. pp. 339, 341. ISBN   978-3-642-11183-9.
  10. ↑ Laron Z, Kauli R, Lapkina L, Werner H (2017). "IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome". Reviews in Mutation Research. 772 (123–133): 123–133. doi:10.1016/j.mrrev.2016.08.002. PMID   28528685.
  11. ↑ Werner H, Lapkina-Gendler L, Laron Z (2017). "Fifty years on: New lessons from the laron syndrome". Israel Medical Association Journal. 19 (1): 6–7. PMID   28457105.
  12. ↑ David A, Hwa V, Metherell L, Netchine I (2011). "Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity". Endocrine Reviews. 32 (4): 472–97. doi: 10.1210/er.2010-0023 . PMID   21525302.
  13. ↑ "Laron Syndrome". GARD: Genetics and Rare Disease Information Center. Retrieved 16 November 2020.
  14. 1 2 3 4 5 Laron Z, Kopchick J (25 November 2010). Laron Syndrome - From Man to Mouse: Lessons from Clinical and Experimental Experience. Springer Science & Business Media. pp. 27–28. ISBN   978-3-642-11183-9 . Retrieved 10 November 2020.
  15. ↑ Shevah O, Kornreich L, Galatzer A, Laron Z (2005). "The intellectual capacity of patients with Laron syndrome (LS) differs with various molecular defects of the growth hormone receptor gene. Correlation with CNS abnormalities". Horm. Metab. Res. 37 (12): 757–60. doi:10.1055/s-2005-921097. PMID   16372230. S2CID   260168044.
  16. 1 2 3 4 5 6 7 8 9 Cohen L (4 July 2016). Growth Hormone Deficiency: Physiology and Clinical Management. Springer International Publishing. pp. 10–17. ISBN   978-3319280387 . Retrieved 16 November 2020.
  17. ↑ Lin S, Li C, Zhang X (2018). "Growth hormone receptor mutations related to individual dwarfism". International Journal of Molecular Sciences. 19 (5): 1433. doi: 10.3390/ijms19051433 . PMC   5983672 . PMID   29748515.
  18. ↑ Laron Z, Kopchick J (25 November 2010). Laron Syndrome - From Man to Mouse: Lessons from Clinical and Experimental Experience. Springer Science & Business Media. pp. 30–46. ISBN   978-3-642-11183-9 . Retrieved 12 November 2020.
  19. ↑ Hwa V, Camacho-Hübner C, Little BM, et al. (2007). "Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene". Horm. Res. 68 (5): 218–24. doi:10.1159/000101334. PMID   17389811. S2CID   46405455.
  20. ↑ Laron, Z.; Kowadlo-Silbergeld, A.; Eshet, R.; Pertzelan, A. (October 1980). "Growth hormone resistance". Annals of Clinical Research. 12 (5): 269–277. ISSN   0003-4762. PMID   6263171.
  21. ↑ Ranke, Michael B.; Wölfle, Joachim; Schnabel, Dirk; Bettendorf, Markus (October 2009). "Treatment of dwarfism with recombinant human insulin-like growth factor-1". Deutsches Arzteblatt International. 106 (43): 703–709. doi:10.3238/arztebl.2009.0703. ISSN   1866-0452. PMC   2780013 . PMID   19946434.
  22. 1 2 3 Wade N (17 February 2011). "Ecuadorean Villagers May Hold Secret to Longevity". The New York Times . ISSN   0362-4331 . Retrieved 17 February 2011.
  23. ↑ "Increlex (mecasermin)". Centerwatch.com. Retrieved 21 November 2014.
  24. ↑ Kemp SF. "Mecasermin rinfabate". Thomson Reuters. Retrieved 5 March 2011.
  25. ↑ Meyer R. "Approval letter (Mecasermin rinfabate)" (PDF). FDA. Retrieved 5 March 2011.
  26. ↑ "Insmed Provides Update on Supply of IPLEX(TM)" . Retrieved 25 August 2017.
  27. ↑ "Report No. 75/20 - Petition 1011-11 - Report on Admissibility" (PDF). www.oas.org. Archived from the original (PDF) on 20 October 2020. Retrieved 9 June 2023.
  28. ↑ Vasco-Toapanta, Gabriel Alejandro; Guanoluisa-Vasco, Alisson Mayerly; Ochoa-Núñez, Gabriela Alejandra; Vasco-Toapanta, Cristhian Santiago (23 May 2024). "Challenges of Access to Treatments: The Case Of Laron Syndrome and the Fight For Social Inclusion". Revista de Gestão Social e Ambiental (in Spanish). 18 (4): e06584–e06584. doi:10.24857/rgsa.v18n4-106. ISSN   1981-982X.
  29. 1 2 Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, et al. (2011). "Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans". Science Translational Medicine. 3 (70): 70ra13. doi:10.1126/scitranslmed.3001845. PMC   3357623 . PMID   21325617.
  30. ↑ Bai N. "Defective Growth Gene in Rare Dwarfism Disorder Stunts Cancer and Diabetes". Scientific American . Retrieved 17 February 2011.
  31. ↑ Winerman L. "Study: Dwarfism Gene May Offer Protection From Cancer, Diabetes". PBS . Retrieved 17 February 2011.
  32. ↑ Bartke A (2012). "Healthy aging: Is smaller better? - A mini-review". Gerontology. 58 (4): 337–343. doi:10.1159/000335166. PMC   3893695 . PMID   22261798.
  33. 1 2 Aguiar-Oliveira M, Bartke A (2019). "Growth hormone deficiency: Health and longevity". Endocrine Reviews. 40 (2): 575–601. doi:10.1210/er.2018-00216. PMC   6416709 . PMID   30576428.
  34. ↑ Rosenbloom A, Guevara Aguirre J, Rosenfeld R, Fielder P (15 November 1990). "The little women of Loja--growth hormone-receptor deficiency in an inbred population of southern Ecuador". The New England Journal of Medicine. 323 (20): 1367–1374. doi: 10.1056/NEJM199011153232002 . PMID   2233903 . Retrieved 10 November 2020.
  35. ↑ Hershkovitz I, Kornreich L, Laron Z (2007). "Comparative skeletal features between Homo floresiensis and patients with primary growth hormone insensitivity (Laron syndrome)". Am. J. Phys. Anthropol. 134 (2): 198–208. doi:10.1002/ajpa.20655. PMID   17596857.
  36. ↑ Culotta E (2007). "Paleoanthropology. The fellowship of the hobbit". Science. 317 (5839): 740–742. doi:10.1126/science.317.5839.740. PMID   17690271. S2CID   89469580.
  37. ↑ Aiello LC (2010). "Five years of Homo floresiensis". American Journal of Physical Anthropology. 142 (2): 167–79. doi:10.1002/ajpa.21255. ISSN   0002-9483. PMID   20229502.
  38. ↑ Laron Z, Kopchick J (25 November 2010). Laron Syndrome - From Man to Mouse: Lessons from Clinical and Experimental Experience. Springer Science & Business Media. pp. 49–50. ISBN   978-3-642-11183-9 . Retrieved 12 November 2020.
  39. ↑ synd/2825 at Who Named It?
  40. ↑ Laron Z, Pertzelan A, Mannheimer S (1966). "Genetic pituitary dwarfism with high serum concentration of growth hormone—a new inborn error of metabolism?". Isr. J. Med. Sci. 2 (2): 152–5. PMID   5916640.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.